Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03976752 · ClinicalTrials.gov registry record · Phase 1
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
A Phase 1 study of HIV/AIDS, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT03976752 is a Phase 1 study of HIV/AIDS that has completed, run by Emory University. The registered enrollment target is 41 participants, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03976752, a Phase 1 study of HIV/AIDS, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to determine if the uptake of anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.
Conditions Studied
Interventions
- DRUG Genvoya
Study Locations (1)
Georgia
- Hope Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2019-03-13 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03976752
The ClinicalTrials.gov registry entry for NCT03976752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,180-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 1 intervention - of which Genvoya is the first listed.
NCT03976752 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT03976752 about?
NCT03976752 is a clinical study titled "Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens". This study is being conducted to determine if the uptake of anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.
What is the current status of trial NCT03976752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2019-03-13. Estimated completion is 2019-09-20.
What conditions does trial NCT03976752 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT03976752?
The interventions under investigation include: Genvoya (DRUG).
Who is sponsoring clinical trial NCT03976752?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03976752 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combinatorial Therapy to Induce an HIV Remission
ACTIVE NOT RECRUITING · Phase 1
-
Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
COMPLETED · Phase 1
-
Transgender Youth and PrEP: PK, Safety, Uptake & Adherence - PK Study
COMPLETED · Phase 1
-
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
COMPLETED · Phase 1
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.